Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...
Hosted on MSN8h
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450 Million-Plus for Trio of Cancer DrugsClinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...
BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...
For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...
The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...
Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...
GlobalData on MSN20h
BridgeBio Oncology and Helix enter definitive merger agreementBridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...
But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...
BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target lifted by Citigroup from $45.00 to $49.00 in a research ...
Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...
Meanwhile, Astellas Pharma’s approach to KRAS G12D degrades the target protein. BridgeBio Oncology brings to the Helix merger about $100 million in cash. That money will be combined with $196 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback